- To administer trails on 26000 volunteers in India
- Only vaccine manufacturer in world with Bio safety Level 3(BSLV3)
- Working on Nasal vaccine too, to be released early next year
New Delhi: Krishna Ella, CMD of Bharat biotech, issued a statement that phase- 3 of clinical trials for corona vaccine ’Covaxin’ has begun on Monday.
Addressing participants in an event held by Indian School of Business, Ella said that they have a plan to come up with a nasal spray vaccine which will be released next year. Now the vaccine which is under phase-3 trials has to be injected twice for each person as a dose. So we need nearly 2.6 billion doses which may take vast time and there would be problems in distribution. The dose of nasal spray is just two drops and can be easily monitored, said Ella.
Trail has begun after Drug controller Of India (DGCI) gave nod for Bharat Biotech which completed Phase 1 &2 with much efficacy ,following proper guidelines and immunology data. For phase-3 trials, Bharat biotech selected nearly 26,000 volunteers across India, which is the largest clinical trial conducted for Covid vaccine in the country.
Clinical trial will take 28 days with volunteers receiving two intramuscular injections who will be randomly assigned to receive Covaxin or placebo. Vaccine is under development with collaboration of ICMR and NIV.
On the other hand, Moderna company(US) issued a statement that their vaccine show 94.5% efficacy in controlling Corona virus, Pfizer also said that their vaccine is 90% effective but experts conclude that it will take time to assess the efficacy of the vaccine under examination.
Astrazeneca which is conducting joint trials along with SII has announced that they will deliver 10 crore samples of vaccines by December end and Pfizer is expected to release two crore of vaccine in US by next month end.